Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial

Vitamin D has shown to play a role in multiple diseases due to its skeletal and extraskeletal actions. Furthermore, vitamin D deficiency has become a worldwide health issue. Few supplementation guidelines mention calcifediol treatment, despite being the direct precursor of calcitriol and the biomarker of vitamin D status. This 1‐year, phase III–IV, double‐blind, randomized, controlled, multicenter clinical trial assessed the efficacy and safety of calcifediol 0.266 mg soft capsules in vitamin D–deficient postmenopausal women, compared to cholecalciferol. Results reported here are from a prespecified interim analysis, for the evaluation of the study's primary endpoint: the percentage of patients with serum 25‐hydroxyvitamin D (25(OH)D) levels above 30 ng/ml after 4 months. A total of 303 patients were enrolled, of whom 298 were included in the intention‐to‐treat (ITT) population. Patients with baseline levels of serum 25(OH)D <20 ng/ml were randomized 1:1:1 to calcifediol 0.266 mg/month for 12 months, calcifediol 0.266 mg/month for 4 months followed by placebo for 8 months, and cholecalciferol 25,000 IU/month for 12 months. At month 4, 35.0% of postmenopausal women treated with calcifediol and 8.2% of those treated with cholecalciferol reached serum 25(OH)D levels above 30 ng/ml (p < 0.0001). The most remarkable difference between both drugs in terms of mean change in serum 25(OH)D levels was observed after the first month of treatment (mean ± standard deviation change = 9.7 ± 6.7 and 5.1 ± 3.5 ng/ml in patients treated with calcifediol and cholecalciferol, respectively). No relevant treatment‐related safety issues were reported in any of the groups studied. These results thus confirm that calcifediol is effective, faster, and more potent than cholecalciferol in raising serum 25(OH)D levels and is a valuable option for the treatment of vitamin D deficiency. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

[1]  R. Bouillon,et al.  “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study” , 2020, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  Free vitamin D correlate better with bone mineral density and thoracolumbar junction osteoporotic vertebral fractures than serum vitamin D , 2020, BMC Musculoskeletal Disorders.

[3]  C. Annweiler,et al.  Vitamin D testing: advantages and limits of the current assays , 2020, European Journal of Clinical Nutrition.

[4]  M. Tuveri,et al.  Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients. , 2019, Minerva endocrinologica.

[5]  P. Mecocci,et al.  Effects of Weekly Supplementation of Cholecalciferol and Calcifediol Among the Oldest-Old People: Findings From a Randomized Pragmatic Clinical Trial , 2019, Nutrients.

[6]  D. Bikle,et al.  Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological Conditions , 2019, Front. Endocrinol..

[7]  K. Cashman.  Vitamin D Deficiency: Defining, Prevalence, Causes, and Strategies of Addressing , 2019, Calcified Tissue International.

[8]  John H. White,et al.  Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions , 2018, Endocrine reviews.

[9]  Geert Carmeliet,et al.  Vitamin D insufficiency: Definition, diagnosis and management. , 2018, Best practice & research. Clinical endocrinology & metabolism.

[10]  R. Bouillon,et al.  Is calcifediol better than cholecalciferol for vitamin D supplementation? , 2018, Osteoporosis International.

[11]  M. Krasowski,et al.  Vitamin D Toxicity: A 16-Year Retrospective Study at an Academic Medical Center , 2018, Laboratory medicine.

[12]  Vladyslav Povoroznyuk,et al.  Vitamin D supplementation guidelines , 2018, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  J. Hernández,et al.  Calcifediol mensual frente a calcifediol quincenal en el tratamiento de pacientes osteoporóticos. Estudio en la vida real , 2018, Revista de Osteoporosis y Metabolismo Mineral.

[14]  D. Bikle,et al.  Current Controversies: Are Free Vitamin Metabolite Levels a More Accurate Assessment of Vitamin D Status than Total Levels? , 2017, Endocrinology and metabolism clinics of North America.

[15]  K. Cashman,et al.  25-Hydroxyvitamin D as a Biomarker of Vitamin D Status and Its Modeling to Inform Strategies for Prevention of Vitamin D Deficiency within the Population. , 2017, Advances in nutrition.

[16]  L. Rejnmark,et al.  Current Assays to Determine Free 25-Hydroxyvitamin D in Serum. , 2017, Journal of AOAC International.

[17]  N. Heureux,et al.  A Direct Assay for Measuring Free 25-Hydroxyvitamin D. , 2017, Journal of AOAC International.

[18]  H. Bischoff-Ferrari,et al.  Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens , 2017, Osteoporosis International.

[19]  A. Chérif,et al.  Why don’t serum vitamin D concentrations associate with BMD by DXA? A case of being ‘bound’ to the wrong assay? Implications for vitamin D screening , 2017, British Journal of Sports Medicine.

[20]  J. Adams,et al.  Effects of Cholecalciferol vs Calcifediol on Total and Free 25-Hydroxyvitamin D and Parathyroid Hormone , 2017, The Journal of clinical endocrinology and metabolism.

[21]  V. Gudnason,et al.  Imminent risk of fracture after fracture , 2017, Osteoporosis International.

[22]  J. M. Quesada-Gomez,et al.  Vitamin D3 and calcidiol are not equipotent , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  X. Nogués,et al.  Clinical practice guidelines for postmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014) , 2015 .

[24]  J. Reginster,et al.  The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) , 2015, Endocrine.

[25]  P. Lips,et al.  Thresholds for Serum 25(OH)D Concentrations With Respect to Different Outcomes. , 2015, The Journal of clinical endocrinology and metabolism.

[26]  E. Orwoll,et al.  Vitamin D and DBP: The free hormone hypothesis revisited , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  R. Francis,et al.  National Osteoporosis Society vitamin D guideline summary. , 2014, Age and ageing.

[28]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[29]  H. Bischoff-Ferrari,et al.  Calcifediol versus vitamin D3 effects on gait speed and trunk sway in young postmenopausal women: a double-blind randomized controlled trial , 2014, Osteoporosis International.

[30]  M. Brandi,et al.  Calcidiol [25(OH)D3]: from diagnostic marker to therapeutical agent , 2013, Current medical research and opinion.

[31]  R. Herr,et al.  A systematic review of vitamin D status in populations worldwide , 2013, British Journal of Nutrition.

[32]  R. Gama,et al.  Vitamin D: a negative acute phase reactant , 2013, Journal of Clinical Pathology.

[33]  C. Cooper,et al.  Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) , 2013, Current medical research and opinion.

[34]  D. Viswanath,et al.  Dietary Reference Intakes for Calcium and Vitamin D , 2012, Pediatrics.

[35]  M. Kiely,et al.  Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults. , 2012, The American journal of clinical nutrition.

[36]  A. Díez-Pérez,et al.  Risk factors for prediction of inadequate response to antiresorptives , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  W. Willett,et al.  Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[39]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[40]  I. Bhan,et al.  Vitamin D–Binding Protein Modifies the Vitamin D–Bone Mineral Density Relationship , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  M. Drezner,et al.  Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. , 2011, The Journal of clinical endocrinology and metabolism.

[42]  F. Leblond,et al.  Reduced hepatic synthesis of calcidiol in uremia. , 2010, Journal of the American Society of Nephrology : JASN.

[43]  S. Ish-shalom,et al.  Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. , 2008, The Journal of clinical endocrinology and metabolism.

[44]  B. Hollis,et al.  25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. , 2008, The American journal of clinical nutrition.

[45]  P. Garnero,et al.  Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. , 2008, Clinical chemistry.

[46]  S. Adami,et al.  [The long term correction of vitamin D deficiency: comparison between different treatments with vitamin D in clinical practice.]. , 2005 .

[47]  D. Felsenberg,et al.  Performance evaluation of automated assays for β-CrossLaps, N-MID-Osteocalcin and intact parathyroidhormone (BIOROSE Multicenter Study) , 2004, Clinical chemistry and laboratory medicine.

[48]  S. Gonnelli,et al.  Validation of a food frequency questionnaire for nutritional calcium intake assessment in Italian women , 2002, European Journal of Clinical Nutrition.